Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors

Phase 1

Completed

• Conditions: Obesity; Metabolism and Nutrition Disorder
• Interventions: Drug: liraglutide

• Registration Number: NCT02207348
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

This trial is conducted in Europe. The aim of this trial is to investigate bioequivalence between single-dose liraglutide administered subcutaneously with two different pen-injectors.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-08
• Study First Submitted: 2014-08-01
• Study First Submitted QC: 2014-08-01
• Study First Posted: 2014-08-04
• Primary Completion: 2014-09
• Study Completion: 2014-09
• Status Verified: 2016-12
• Last Update Submitted: 2016-12-08
• Last Update Posted: 2016-12-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• Male or female, age 18-60 years (both inclusive) at the time of signing informed consent
• Body mass index (BMI) greater than or equal to 27.0 and less than 35.0 kg/m^2
• Bodyweight up to 130.0 kg (inclusive)
• HbA1c (glycosylated haemoglobin) below 6.5%

Exclusion Criteria

• Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method. Only highly effective methods of birth control are accepted (i.e. one that results in less than 1% per year failure rate when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices), or sexual abstinence or vasectomised partner
• History or presence of cancer, or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrine (incl. diabetes), haematological, dermatological, venereal, neurological, psychiatric diseases or other major disorders that might have impact on the trial, as judged by the investigator
• Use of any prescription or non-prescription medication, except for paracetamol, acetylsalicylic acid, contraceptives and vitamins (but including mega-dose vitamin therapy, as judged by the investigator) within 2 weeks before the trial defined as screening
• Significant history of alcoholism or drug/chemical abuse within 1 year from screening, or a positive result of the urine drug screen or alcohol breath test, or consuming more than 21 units of alcohol per week (one unit of alcohol equals about 250 mL of beer or lager, one glass of wine (120 mL), or 20 mL spirits)
• Smoking more than 5 cigarettes, or the equivalent, per day and unable to refrain from smoking during the in-house periods

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Liraglutide 0.6 mg s.c. with FlexPen®	liraglutide	-
Liraglutide 0.6 mg s.c. with the PDS290 pen-injector	liraglutide	-

Primary Outcome Measures

Name	Time	Method
Area under the liraglutide plasma concentration time curve from 0 to last quantifiable observation (tz) after single dose	0-72 hours following administration of 0.6 mg liraglutide
Maximum observed liraglutide plasma concentration after single dose	0-72 hours following administration of 0.6 mg liraglutide

Secondary Outcome Measures

Name	Time	Method
Number of treatment emergent adverse events (TEAEs)	From baseline to follow-up (up to 3 weeks). Baseline is defined as time of first trial drug administration at Visit 2

Trial Locations

Locations (1)

Novo Nordisk Investigational Site; 🇩🇪 Neuss, Germany